Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status:
Completed
Trial end date:
2017-07-08
Target enrollment:
Participant gender:
Summary
The purpose of the study was to determine whether treatment with a PI3K inhibitor plus
letrozole led to an increase in pathologic clinical response and Objective Response Rate
compared to treatment with placebo plus letrozole in patients with Breast cancer.